🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,046 results for “infusion” Clear

  1. CYCLOPHOSPHAMIDE, Paclitaxel 6 mg/mL concentrate for solution for infusion, Doxorubicin 2 mg/ml Concentrate for Solution for Infusion, DURVALUMAB, Oleclumab_IJB2

    The George Institute

    Luminal B Breast Cancer

    phase 2 small molecule active

    1 trial
  2. Cabazitaxel Accord 20 mg/ml concentrate for solution for infusion, Lutathera 370 MBq/mL solution for infusion, Xofigo 1100 kBq/mL solution for injection, Lynparza 150 mg film-coated tablets, Docetaxel Aurovitas 20 mg/ml concentrado para solución para perfusión, BAY 1841788

    Ningbo Cancer Hospital

    Metastatic castration-resistant prostate cancer

    phase 2 small molecule active

    1 trial
  3. Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion, PACLITAXEL, TOPOTECAN, farletuzumab ecteribulin

    Bristol-Myers Squibb Australia Pty Ltd

    Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    phase 2 small molecule active

    1 trial
  4. Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion, TRABECTEDIN

    Fondazione Telethon ETS

    recurrent ovarian cancer

    phase 2 small molecule active

    1 trial
  5. Calcio levofolinato Teva Generics 175 mg polvere per soluzione per infusione, BEVACIZUMAB , ZALTRAP 25 mg/ml concentrate for solution for infusion, Oxaliplatin 5 mg/ml concentrate for solution for infusion, Stivarga 40 mg film-coated tablets, FLUOROURACIL , FLUOROURACIL , Irinotecan Accord 20 mg/ml concentrato per soluzione per infusione, CAPECITABINE

    Fondazione Telethon ETS

    Patients with metastatic colorectal cancer (mCRC) RAS-mutant

    phase 2 small molecule active

    1 trial
  6. Calcium Folinate 10 mg/ml Solution for injection or infusion, Irinotecanhydrochloridetrihydraat Hikma 20 mg/ml, concentraat voor oplossing voor infusie, Fluorouracil Accord 50 mg/ml, oplossing voor injectie of infusie, Avastin 25 mg/ml concentrate for solution for infusion., Oxaliplatin Eugia 5 mg/ml concentraat voor oplossing voor infusie

    Disc Medicine

    Patients with colorectal peritoneal metastases with a PCI-score of 1-20

    phase 2 small molecule active

    1 trial
  7. Calciumfolinat HEXAL 10 mg/ml Injektionslösung, Irinotecan HCl AqVida 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, BNT321, FLUOROURACIL, Oxaliplatin AqVida 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    BioNTech SE

    Resected (R0 or R1) pancreatic ductal adenocarcinoma

    phase 2 small molecule active

    1 trial
  8. Calquence 100 mg hard capsules, IMBRUVICA 420 mg film-coated tablets, IMBRUVICA 140 mg hard capsules, IMBRUVICA 140 mg hard capsules, BRUKINSA 80 mg hard capsules, Lisaftoclax, Calquence 100 mg hard capsules, MabThera 500 mg concentrate for solution for infusion, Lisaftoclax, Lisaftoclax

    Lacuna Pharma Pty Ltd

    Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).

    phase 2 small molecule active

    1 trial
  9. Campto 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Campto 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, DEXAMETHASONE , Temodal 180 mg hard capsules, Temodal 5 mg hard capsules, Temodal 140 mg hard capsules, Temodal 100 mg hard capsules, Campto 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Temodal 20 mg hard capsules, Temodal 250 mg hard capsules

    Inhibrx Biosciences

    Advanced or metastatic solid tumors

    phase 2 small molecule active

    1 trial
  10. Capecitabina KERN PHARMA 150 mg comprimidos recubiertos con película EFG, Oxaliplatin Hospira 5 mg/ml concentrate for solution for infusion, Oxaliplatin Hospira 5 mg/ml concentrate for solution for infusion, Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG, Irinotecán Hospira 20 mg/mL concentrado para solución para perfusión EFG., Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG, Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG, Capecitabina

    The George Institute

    Localised Colon Cancer (stage II-III)

    phase 2 small molecule active

    1 trial
  11. Carboplat onkovis 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Etomedac 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung

    Ningbo Cancer Hospital

    Stage IIA/B seminoma

    phase 2 small molecule active

    1 trial
  12. Carboplat onkovis 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel onkovis, 6 mg/ml, Konzentrat zur Herstellung einer Infusionslösung, Doce onkovis 20 mg/ ml Konzentrat zur Herstellung einer Infusionslösung, IMFINZI 50 mg/mL concentrate for solution for infusion., Pemetrexed medac 500 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, Vinorelbin onkovis 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed medac 100 mg Pulver für ein Konzentrat zur Herst

    Ningbo Cancer Hospital

    Resectable, locally advanced non-small cell lung cancer (NSCLC, N2)

    phase 2 small molecule active

    1 trial
  13. Carboplatin 10 mg/ml Concentrate for Solution for Infusion, Avastin 25 mg/ml concentrate for solution for infusion., Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, Zejula 100 mg hard capsules, Zejula 100 mg hard capsules, Zejula 100 mg hard capsules, Avastin 25 mg/ml concentrate for solution for infusion.

    TESARO Bio Netherlands B.V.

    Ovarian Neoplasms

    phase 2 small molecule active

    1 trial
  14. Carboplatin 10 mg/ml Concentrate for Solution for Infusion, DOMVANALIMAB, Paclitaxel 6 mg/ml concentrate for solution for infusion, Zimberelimab

    Gilead Sciences Pty Limited

    Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial
  15. Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, JNJ-61186372, Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, KEYTRUDA 25 mg/mL concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Janssen-Cilag International N.V.

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial
  16. Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Paclitaxel Bendalis 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Mycofit, 250 mg, kapsułki twarde, Remsima 100 mg powder for concentrate for solution for infusion, volrustomig, Cyramza 10 mg/ml concentrate for solution for infusion

    AstraZeneca AB

    Solid Tumors, SQ, NSQ NSCLC

    phase 2 small molecule active

    1 trial
  17. Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, Alectinib (Alecensa), Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Pemetrexed Pfizer 25 mg/ml concent

    Hoffmann-La Roche

    Resectable Stage I-III Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial
  18. Carboplatino Hikma 10 mg/ml soluzione per infusione, Avastin 25 mg/ml concentrate for solution for infusion., Cisplatino Accord Healthcare Italia 1 mg/ml concentrato per soluzione per infusione, JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Tumours, Gynecological

    phase 2 small molecule active

    1 trial
  19. Cell infusion intraportal mononuclear bone marrow autologous and portal embolization of the affected segments.

    Lxo Ireland Designated Activity Company

    Liver Transplant Rejection

    phase 2 other completed

    1 trial
  20. Cemiplimab and Fianlimab - 1, Fianlimab, Cemiplimab & Fianlimab - 2, LIBTAYO 350 mg concentrate for solution for infusion., Placebo for Fianlimab

    Lacuna Pharma Pty Ltd

    Melanoma

    phase 2 small molecule active

    1 trial
  21. Cemiplimab and Fianlimab - 1, Placebo, LIBTAYO 350 mg concentrate for solution for infusion., PEMETREXED, CARBOPLATIN, CISPLATIN, Cemiplimab & Fianlimab - 2, PACLITAXEL

    Lacuna Pharma Pty Ltd

    Resectable Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial
  22. Cevostamab, RoActemra 20 mg/mL concentrate for solution for infusion

    Hoffmann-La Roche

    Relapsed/Refractory Multiple Myeloma

    phase 2 small molecule active

    1 trial
  23. Cinryze 500 IU powder and solvent for solution for injection, Saline Solution Basi 9 mg/ml solution for infusion

    Disc Medicine

    Traumatic Brain Injury

    phase 2 small molecule active

    1 trial
  24. Cisplatino Accord Healthcare Italia 1 mg/ml concentrato per soluzione per infusione, DOXORUBICINA ACCORD HEALTHCARE ITALIA 2 mg/ml concentrato per soluzione per infusione

    Sana Biotechnology

    Pleural carcinosis

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources